keyword
MENU ▼
Read by QxMD icon Read
search

DMARD

keyword
https://www.readbyqxmd.com/read/28537473/anakinra-in-the-treatment-of-patients-with-refractory-scleritis-a-pilot-study
#1
C Bottin, A Fel, N Butel, F Domont, A L Remond, L Savey, V Touitou, J F Alexandra, P LeHoang, P Cacoub, B Bodaghi, D Saadoun
PURPOSE: This study aimed to evaluate the safety and efficacy of anakinra for severe and refractory scleritis. METHODS: Ten patients with severe (i.e. at least 2 ocular relapses per year despite treatment) and refractory [i.e. at least to one disease modifying antirheumatic drugs (DMARDS)] scleritis were treated with anakinra (100 mg/day subcutaneously). Scleritis was associated with inflammatory systemic diseases in 60% of cases. The remission rate defined the primary outcome...
May 24, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28526972/patient-experiences-attitudes-and-expectations-towards-receiving-information-about-anti-tnf-medication-a-quantitative-study
#2
Jon Packham, Paul Arkell, Tom Sheeran, Ann Brownfield, Anthony Cadwgan, Sarah Ryan
The objective of the study was to measure patient attitudes and experience of information received during drug counselling for rheumatoid arthritis (RA) medications. This is a cross-sectional UK postal questionnaire study. Three RA patient groups-disease-modifying antirheumatic drugs (DMARDs) only, first anti-tumour necrosis factor (anti-TNF) and failed anti-TNF-were sent postal questionnaires. Data on patient history/demographics, drug counselling experience, knowledge of drug side effects, attitudes to vaccinations, cancer screening and blood borne virus testing was collected; 264/679 (39%) patients responded (median age 65 years, 66% female, median disease duration 15 years)...
May 19, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28524619/use-of-complementary-and-alternative-medicines-is-associated-with-delay-to-initiation-of-disease-modifying-anti-rheumatic-drug-therapy-in-early-inflammatory-arthritis
#3
Manjari Lahiri, Amelia Santosa, Lay Kheng Teoh, Jane A Clayton, Sheen Yee Lim, Gim Gee Teng, Peter P M Cheung
OBJECTIVES: To study the predictors of complementary and alternative medicine (CAM) use in patients with early inflammatory arthritis (EIA), and its impact on delay to initiation of disease-modifying anti-rheumatic drugs (DMARD). METHODS: Data were collected prospectively from EIA patients aged ≥ 21 years. Current or prior CAM use was ascertained by face-to-face interview. Predictors of CAM use and its effect on time to DMARD initiation were determined by multivariate logistic regression and Cox proportional hazards, respectively...
May 19, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28521841/tnf-inhibitors-appear-to-inhibit-disease-progression-and-improve-outcome-in-takayasu-arteritis-an-observational-population-based-time-trend-study
#4
Birgir Gudbrandsson, Øyvind Molberg, Øyvind Palm
BACKGROUND: Magnetic resonance imaging (MRI) and computed tomography (CT) angiography have now largely replaced interventional angiography in the diagnoses and follow up of Takayasu arteritis (TAK) but data on the effects of this change of imaging method on diagnostic delay and vascular damage, and detailed data on the effect of different treatment regimens on the accumulation of vascular damage are missing. The aim of this study was to assess time trends in diagnostic delay, therapeutic approaches, arterial lesion accrual, persistent disease activity and remission rates in TAK...
May 18, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28516890/tocilizumab-in-the-treatment-of-patients-with-rheumatoid-arthritis-in-real-clinical-practice-results-of-an-italian-observational-study
#5
Roberto Caporali, Luca Idolazzi, Stefano Bombardieri, Gianfranco Ferraccioli, Roberto Gerli, Marco Govoni, Marco Matucci Cerinic, Giovanni Pomponio, Fausto Salaffi, Rossella Tirri, Francesca Benaglio, Laura Bianchino, Piercarlo Sarzi-Puttini
OBJECTIVES: To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice. METHODS: TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion. RESULTS: 322 RA patients were enrolled in 59 Italian centres (mean age: 55...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516887/tenosynovitis-in-rheumatoid-arthritis-patients-on-biologic-treatment-involvement-and-sensitivity-to-change-compared-to-joint-inflammation
#6
Hilde Berner Hammer, Tore K Kvien, Lene Terslev
OBJECTIVES: Extensor carpi ulnaris (ECU) and tibialis posterior (TP) tendons are often involved in RA and the present aim was to examine by ultrasound (US) their frequency of inflammation and sensitivity to change in comparison to joint involvement as well as clinical examinations. METHODS: US, clinical and laboratory assessments were performed when starting biologic DMARD (bDMARD) and after 1, 2, 3, 6 and 12 months including bilateral grey-scale (GS) and power Doppler (PD) semi-quantitatively (0-3) scoring of ECU and TP tendons and 18 joints...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516872/glucocorticoid-sparing-effect-of-first-year-anti-tnf%C3%AE-treatment-in-rheumatoid-arthritis-corpus-cohort
#7
Carole Duquenne, Daniel Wendling, Jean Sibilia, Chantal Job-Deslandre, Loic Guillevin, Jacques Benichou, René Marc Flipo, Francis Guillemin, Alain Saraux
OBJECTIVES: Anti-TNFα agents are indicated in selected patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate and particularly when glucocorticoids are mandatory. We evaluated whether a glucocorticoid-sparing effect occurred during the first year of anti-TNF-α therapy. METHODS: Between 2007 and 2009, the French multicentre, longitudinal, prospective, observational, population-based CORPUS cohort included biologic-naive patients with inflammatory joint disease...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516868/predicting-responses-in-patients-with-rheumatoid-arthritis-to-disease-modifying-agents-using-baseline-clinical-data
#8
Nicola J Gullick, Aneela N Mian, Fowzia Ibrahim, David Walker, Andrew Hassell, Patrick D W Kiely, David A Walsh, Adam Young, David L Scott
OBJECTIVES: The optimal treatment for active rheumatoid arthritis (RA) is unresolved, particularly in early RA. We used data from an observational cohort to develop the simple predictor algorithm and evaluated its application in two completed clinical trials in early and established RA. We assessed whether using a simple algorithm can identify patients who have persisting active disease despite treatment with disease-modifying drugs (DMARDs). We also examined if patients who have lower likelihoods of persisting active RA are likely to benefit from intensive treatment...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28508282/malignancy-incidence-management-and-prevention-in-patients-with-rheumatoid-arthritis
#9
REVIEW
Katelynn M Wilton, Eric L Matteson
Traditional and biologic disease-modifying antirheumatic drugs (DMARDs) are effective medications for the management of rheumatoid arthritis (RA). However, the effects of these medications on immune function raises concern that they may increase long-term cancer risk. The baseline risk for some cancers appears to differ in patients with RA compared to the general population, with the former having an increased risk of lymphoma, lung cancer and renal cancer, but a decreased risk of colorectal and breast cancer...
May 15, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28505163/anti-citrullinated-peptide-antibodies-are-the-strongest-predictor-of-clinically-relevant-radiographic-progression-in-rheumatoid-arthritis-patients-achieving-remission-or-low-disease-activity-a-post-hoc-analysis-of-a-nationwide-cohort-in-japan
#10
Tomohiro Koga, Akitomo Okada, Takaaki Fukuda, Toshihiko Hidaka, Tomonori Ishii, Yukitaka Ueki, Takao Kodera, Munetoshi Nakashima, Yuichi Takahashi, Seiyo Honda, Yoshiro Horai, Ryu Watanabe, Hiroshi Okuno, Toshiyuki Aramaki, Tomomasa Izumiyama, Osamu Takai, Taiichiro Miyashita, Shuntaro Sato, Shin-Ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Tomoki Origuchi, Hideki Nakamura, Kiyoshi Aoyagi, Katsumi Eguchi, Atsushi Kawakami
OBJECTIVES: To determine prognostic factors of clinically relevant radiographic progression (CRRP) in patients with rheumatoid arthritis (RA) achieving remission or low disease activity (LDA) in clinical practice. METHODS: Using data from a nationwide, multicenter, prospective study in Japan, we evaluated 198 biological disease-modifying antirheumatic drug (bDMARD)-naïve RA patients who were in remission or had LDA at study entry after being treated with conventional synthetic DMARDs (csDMARDs)...
2017: PloS One
https://www.readbyqxmd.com/read/28502927/mizoribine-synchronized-methotrexate-therapy-should-be-considered-when-treating-rheumatoid-arthritis-patients-with-an-inadequate-response-to-various-combination-therapies
#11
Keigo Ikeda, Kozo Watanabe, Takuya Hirai, Kana Tanji, Tomoko Miyashita, Shihoko Nakajima, Kaori Uomori, Shinji Morimoto, Kenji Takamori, Hideoki Ogawa, Yoshinari Takasaki, Iwao Sekigawa
Objective The objective of this study was to confirm the efficacy of low-dose mizoribine (MZR), an inhibitor of inosine monophosphate dehydrogenase, as part of synchronized methotrexate (MTX) therapy for rheumatoid arthritis (RA) patients with an inadequate response to various combination therapies of MTX, other synthetic disease-modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. Methods Low-dose MZR was administered to 56 uncontrolled RA patients being treated with MTX and various biological DMARDs...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28496328/association-between-use-of-disease-modifying-antirheumatic-drugs-and-diabetes-in-patients-with-ankylosing-spondylitis-rheumatoid-arthritis-or-psoriasis-psoriatic-arthritis-a-nationwide-population-based-cohort-study-of-84-989-patients
#12
Hsin-Hua Chen, Der-Yuan Chen, Chi-Chen Lin, Yi-Ming Chen, Kuo-Lung Lai, Ching-Heng Lin
PURPOSE: The aim of this study is to investigate the association between the use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PSA). PATIENTS AND METHODS: This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PS/PSA who initiated treatment with anti-tumor necrosis factor (anti-TNF) drugs or nonbiologic DMARDs...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28495399/evaluation-of-toll-like-receptor-gene-family-variants-as-prognostic-biomarkers-in-rheumatoid-arthritis
#13
Silvia Torices, Lorena Alvarez-Rodríguez, Ignacio Varela, Pedro Muñoz, Alejandro Balsa, M López-Hoyos, Víctor Martinez-Taboada, Jose L Fernández-Luna
Rheumatoid arthritis (RA) is a systemic autoimmune disease whose main feature is persistent joint inflammation. Toll-like receptors (TLRs) play critical roles in the activation of innate and adaptive immune responses, and influence the activity of NFκB, a key player in chronic inflammation. We aimed at investigating the association of TLR allelic variants with susceptibility and severity of RA through a systematic, high-throughput, analysis of TLR genes. All coding exons and flanking regions of nine members of the TLR family (TLR1-9) were analyzed in 66 patients with RA and 30 healthy controls by next generation sequencing...
May 7, 2017: Immunology Letters
https://www.readbyqxmd.com/read/28487504/obinutuzumab-is-effective-in-chronic-lymphocytic-leukemia-and-rheumatoid-arthritis-after-rituximab-failure-a-case-report
#14
Curtis Lachowiez, Atul Deodhar, Eliana Kozin, Stephen Spurgeon
BACKGROUND Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting older adults. As such, many of these patients suffer from co-existing disease states, and the provider must take these comorbidities into account when determining a treatment regimen. The widespread use of monoclonal antibodies (mAbs) has drastically changed the treatment landscape of multiple diseases, ranging from leukemia to autoimmune conditions such as rheumatoid arthritis. CASE REPORT We present the case of a patient who had progression of his CLL and rheumatoid symptoms on rituximab therapy, and was subsequently treated with the second-generation anti-CD20 antibody obinutuzumab...
May 10, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28485176/the-role-of-il-17-in-the-treatment-of-psoriatic-arthritis
#15
Ennio Lubrano, Fabio Massimo Perrotta
Psoriatic arthritis (PsA) is a chronic inflammatory articular disease characterized by psoriasis, synovitis and enthesitis. Current treatment of PsA is mainly based on the use of classical and biological DMARDs; however, 30-40% of patients could not respond to these or have a loss of response. Areas covered: Recently, the discovery of new pathogenic mechanisms have made possible the development of new drugs that target the IL-17 with the possibility to interfere with the Th17 cells that are considered the cell type mainly involved in the development of the inflammation in PsA...
May 16, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28482738/hepcidin-plasma-levels-are-not-associated-with-changes-in-haemoglobin-in-early-rheumatoid-arthritis-patients
#16
R D Østgård, H Glerup, A G Jurik, T W Kragstrup, K Stengaard-Pedersen, M L Hetland, K Hørslev-Petersen, P Junker, B W Deleuran
OBJECTIVE: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. METHOD: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured...
May 9, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28481462/biologics-or-tofacitinib-for-people-with-rheumatoid-arthritis-naive-to-methotrexate-a-systematic-review-and-network-meta-analysis
#17
REVIEW
Jasvinder A Singh, Alomgir Hossain, Amy S Mudano, Elizabeth Tanjong Ghogomu, Maria E Suarez-Almazor, Rachelle Buchbinder, Lara J Maxwell, Peter Tugwell, George A Wells
BACKGROUND: Biologic disease-modifying anti-rheumatic drugs (biologics) are highly effective in treating rheumatoid arthritis (RA), however there are few head-to-head biologic comparison studies. We performed a systematic review, a standard meta-analysis and a network meta-analysis (NMA) to update the 2009 Cochrane Overview. This review is focused on the adults with RA who are naive to methotrexate (MTX) that is, receiving their first disease-modifying agent. OBJECTIVES: To compare the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib versus comparator (methotrexate (MTX)/other DMARDs) in people with RA who are naive to methotrexate...
May 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28472115/efficacy-and-safety-at-24-weeks-of-daily-clinical-use-of-tofacitinib-in-patients-with-rheumatoid-arthritis
#18
Naoki Iwamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Shoichi Fukui, Masataka Umeda, Ayako Nishino, Yoshiro Horai, Tomohiro Koga, Shin-Ya Kawashiri, Toshiyuki Aramaki, Kunihiro Ichinose, Yasuko Hirai, Mami Tamai, Hideki Nakamura, Kaoru Terada, Tomoki Origuchi, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami
OBJECTIVE: We evaluated the efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) in a real-world setting. METHODS: Seventy consecutive patients, for whom tofacitinib was initiated between November 2013 and May 2016, were enrolled. All patients fulfilled the 2010 ACR/EULAR classification criteria for RA. All patients received 5 mg of tofacitinib twice daily and were followed for 24 weeks. Clinical disease activity indicated by disease activity score (DAS)28-ESR, the simplified disease activity index, and the clinical disease activity index as well as adverse events (AEs) were evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28465766/biologic-disease-modifying-antirheumatic-drugs-in-a-national-privately-insured-population-utilization-expenditures-and-price-trends
#19
Christopher B Atzinger, Jeff J Guo
BACKGROUND: Spending on biologic drugs is a significant driver of drug expenditures for payers in private health plans. Biologic disease-modifying antirheumatic drugs (DMARDs) are some of the most effective and costly treatments in a physician's arsenal. Understanding the total annual expenditure, the average cost per prescription, and the impact of cost-sharing is important for drug benefit managers. OBJECTIVE: To assess drug utilization, expenditures, out-of-pocket (OOP) cost, and price trends of biologic DMARDs in patients with rheumatoid arthritis (RA) in a large managed care organization...
February 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28465764/sociodemographic-determinants-of-out-of-pocket-expenditures-for-patients-using-prescription-drugs-for-rheumatoid-arthritis
#20
Kumar Mukherjee, Khalid M Kamal
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease that has a substantial economic impact on patients. Patients with RA are at an increased risk for disability and for loss of income. The inclusion of biologic drugs in RA therapy has increased the cost of treatment. Little is known about the relationship between sociodemographic characteristics and the out-of-pocket (OOP) expenditures for prescription drugs for patients with RA, including biologics, disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics...
February 2017: American Health & Drug Benefits
keyword
keyword
61414
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"